JP2022513562A - 肺炎連鎖球菌の精製された莢膜多糖 - Google Patents

肺炎連鎖球菌の精製された莢膜多糖 Download PDF

Info

Publication number
JP2022513562A
JP2022513562A JP2021516582A JP2021516582A JP2022513562A JP 2022513562 A JP2022513562 A JP 2022513562A JP 2021516582 A JP2021516582 A JP 2021516582A JP 2021516582 A JP2021516582 A JP 2021516582A JP 2022513562 A JP2022513562 A JP 2022513562A
Authority
JP
Japan
Prior art keywords
kda
polysaccharide
streptococcus pneumoniae
protein
pneumococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021516582A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020058963A5 (https=
JP2022513562A5 (https=
Inventor
ブルキ，ラジェンダー
カンディマラ，ヴィヴェーク・バブ
スリラマン，ラジャン
マトゥール，ラメシュ・ベンカト
マンテナ，ナレンダー・デーブ
ダトラ，マヒマ
サンガレッディ，ベーラパンドゥ
Original Assignee
バイオロジカル イー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69886702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022513562(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイオロジカル イー リミテッド filed Critical バイオロジカル イー リミテッド
Publication of JP2022513562A publication Critical patent/JP2022513562A/ja
Publication of JPWO2020058963A5 publication Critical patent/JPWO2020058963A5/ja
Publication of JP2022513562A5 publication Critical patent/JP2022513562A5/ja
Priority to JP2024130732A priority Critical patent/JP2024160305A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
JP2021516582A 2018-09-23 2019-09-23 肺炎連鎖球菌の精製された莢膜多糖 Withdrawn JP2022513562A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024130732A JP2024160305A (ja) 2018-09-23 2024-08-07 肺炎連鎖球菌の精製された莢膜多糖

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841031654 2018-09-23
IN201841031654 2018-09-23
IN201841031653 2018-09-23
IN201841031653 2018-09-23
PCT/IB2019/058036 WO2020058963A1 (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024130732A Division JP2024160305A (ja) 2018-09-23 2024-08-07 肺炎連鎖球菌の精製された莢膜多糖

Publications (3)

Publication Number Publication Date
JP2022513562A true JP2022513562A (ja) 2022-02-09
JPWO2020058963A5 JPWO2020058963A5 (https=) 2022-10-03
JP2022513562A5 JP2022513562A5 (https=) 2022-10-03

Family

ID=69886702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516582A Withdrawn JP2022513562A (ja) 2018-09-23 2019-09-23 肺炎連鎖球菌の精製された莢膜多糖
JP2024130732A Pending JP2024160305A (ja) 2018-09-23 2024-08-07 肺炎連鎖球菌の精製された莢膜多糖

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024130732A Pending JP2024160305A (ja) 2018-09-23 2024-08-07 肺炎連鎖球菌の精製された莢膜多糖

Country Status (12)

Country Link
US (2) US12048739B2 (https=)
EP (1) EP3852795A4 (https=)
JP (2) JP2022513562A (https=)
KR (1) KR102879391B1 (https=)
CN (1) CN113164581A (https=)
AU (1) AU2019341723C1 (https=)
BR (1) BR112021005425A2 (https=)
MX (1) MX2021003358A (https=)
MY (1) MY206212A (https=)
PH (1) PH12021550539A1 (https=)
WO (1) WO2020058963A1 (https=)
ZA (1) ZA202101663B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2021014710A (es) * 2019-06-05 2022-01-18 Merck Sharp & Dohme Llc Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo.
PH12022552827A1 (en) * 2020-05-01 2024-02-12 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
JP2023546446A (ja) * 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
KR20230097160A (ko) * 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022169787A1 (en) * 2021-02-04 2022-08-11 Merck Sharp & Dohme Llc Lipid nanoparticle adjuvant composition for pneumococcal conjugate vaccines
CN120202227A (zh) * 2022-09-19 2025-06-24 生物学E有限公司 纯化荚膜多糖的方法
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509081A (ja) * 2012-12-20 2016-03-24 ファイザー・インク 糖複合化方法
JP2017504661A (ja) * 2014-01-21 2017-02-09 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート
WO2017067962A1 (en) * 2015-10-21 2017-04-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2018064444A1 (en) * 2016-09-30 2018-04-05 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
WO2018156491A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
US10280409B2 (en) 2014-11-20 2019-05-07 Biological E Limited Codon optimized polynucleotide for high level expression of CRM197
KR102775456B1 (ko) 2015-11-09 2025-02-28 바이오로지칼 이 리미티드 생물학적 활성 재조합 캐리어 단백질을 회수하기 위한 산업적 확장성이 있는 방법
ES3024474T3 (en) * 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
WO2018193475A2 (en) 2017-04-22 2018-10-25 Biological E Limited An improved method for high level production of crm
EP3678655A4 (en) 2017-09-07 2021-05-05 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
PT3678654T (pt) 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509081A (ja) * 2012-12-20 2016-03-24 ファイザー・インク 糖複合化方法
JP2017504661A (ja) * 2014-01-21 2017-02-09 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート
WO2017067962A1 (en) * 2015-10-21 2017-04-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2018064444A1 (en) * 2016-09-30 2018-04-05 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
WO2018156491A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates

Also Published As

Publication number Publication date
AU2019341723C1 (en) 2026-01-22
WO2020058963A1 (en) 2020-03-26
PH12021550539A1 (en) 2022-02-21
US20210346488A1 (en) 2021-11-11
US12048739B2 (en) 2024-07-30
KR102879391B1 (ko) 2025-10-30
US20240325516A1 (en) 2024-10-03
JP2024160305A (ja) 2024-11-13
US12465632B2 (en) 2025-11-11
MX2021003358A (es) 2021-05-27
CN113164581A (zh) 2021-07-23
AU2019341723A1 (en) 2021-05-20
EP3852795A1 (en) 2021-07-28
AU2019341723B2 (en) 2024-03-21
KR20210062669A (ko) 2021-05-31
ZA202101663B (en) 2024-08-28
BR112021005425A2 (pt) 2021-06-15
MY206212A (en) 2024-12-04
EP3852795A4 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
JP7403576B2 (ja) 多糖類－タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
US12465632B2 (en) Purified capsular polysaccharides of Streptococcus pneumoniae
JP2020533299A (ja) キャリアタンパク質へのコンジュゲーションのための肺炎球菌多糖の製剤方法
CN113194987B (zh) 多价肺炎球菌多糖-蛋白缀合的疫苗
WO2020157772A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
US20230101892A1 (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
EA048093B1 (ru) Очищенные капсульные полисахариды streptococcus pneumoniae
OA20178A (en) Purified capsular polysaccharides of streptococcus pneumoniae.
HK40050226B (zh) 多价肺炎球菌多糖-蛋白缀合的疫苗
EA047156B1 (ru) Мультивалентная вакцина на основе конъюгата пневмококковый полисахарид-белок
EA048146B1 (ru) Композиции поливалентной пневмококковой вакцины, содержащие конъюгаты полисахарид-белок
HK40050226A (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
OA20315A (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine.
EA040051B1 (ru) Композиции поливалентной пневмококковой вакцины, содержащие конъюгаты полисахарид-белок
OA19223A (en) Multivalent pneumococcal vaccine compositions comprising polysaccharideprotein conjugates.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240408

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240808